Drug delivery systems for the development of prospective mucosal vaccine

DOI Web Site 41 References
  • Kunisawa Jun
    Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo
  • Kiyono Hiroshi
    Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo

Bibliographic Information

Other Title
  • ワクチンとＤＤＳ　　ＤＤＳ技術を基盤とした次世代型粘膜ワクチンの開発
  • DDS技術を基盤とした次世代型粘膜ワクチンの開発
  • DDS ギジュツ オ キバン ト シタ ジセダイガタ ネンマク ワクチン ノ カイハツ

Search this article

Abstract

Mucosal vaccine has been considered to be a novel prospective vaccine against infectious diseases (e.g., influenza and infectious enteritis) because it can induce double layered protective immunity through both mucosal and systemic immune systems. Recent advances in DDS technology and progresses in cellular and molecular understanding of the mucosal immune system allow us to overcome several problems in the development of mucosal vaccine.<BR>Especially, DDS not only protects antigen from harsh conditions of the mucosal environment but also delivers antigen efficiently to mucosa-associated lymphoid tissue (MALT) including Peyer's patches and nasopharynx-associated lymphoid tissue (NALT), initiation sites for the antigen-specific immune response. In this review, we shed light on the dynamics of mucosal immune system and recent achievements toward the development of DDS-based mucosal vaccine.

Journal

  • Drug Delivery System

    Drug Delivery System 23 (2), 116-122, 2008

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(41)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top